From Vol13 No7 NNRTI choice: has 2NN changed our practice?<\/strong> Triple diagnosis: dual diagnosis and HIV disease, Part 1<\/strong> Patients who want to stop their medications: treatment interruption in HIV infection<\/strong> When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies<\/strong> Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy<\/strong> Clinically relevant interpretation of genotype for resistance to abacavir<\/strong> Structured treatment interruption in patients with multidrug-resistant HIV<\/strong>
\n http:\/\/www.medscape.com\/viewpublication\/93_toc?vol=13&iss=7<\/a><\/p>\n
\nGraeme J. Moyle
\nHas 2NN settled any arguments? Did one of the drugs win?<\/p>\n
\nAntoine B. Douaihy and others
\nSubstance use disorders and psychiatric illness commonly co-occur in what is known as dual diagnosis. With the spread of HIV infection in persons with dual diagnoses, the triple diagnosis has emerged as a clinically challenging condition for primary care physicians, addiction medicine specialists, and psychiatrists.<\/p>\n
\nSusan C. Bal<\/p>\nAIDS<\/h2>\n
\nAndrew Phillips and others. AIDS 2003; 17(13):1863-1869
\nhttp:\/\/www.natap.org\/2003\/sept?090203_2.htm<\/a><\/p>\n
\nDario Bruera and colleagues. AIDS 2003; 17(13):1917-1923
\n http:\/\/www.natap.org\/2003\/aug\/082503_4.htm<\/a><\/p>\n
\n http:\/\/mp.medscape.com\/cgi-bin1\/DM\/y\/hdSX0EIgTL0D1N0FgT70AA<\/a>
\nThe authors present a new strategy for the analysis of correlation between genotype profile at baseline and virologic response.
\nAIDS 17(12) 2003<\/p>\nNEJM<\/h2>\n
\nJody Lawrence and others
\nNEJM, Vol 349:837-846, Aug 28, 2003, Number 9
\n http:\/\/www.natap.org\/2003\/aug\/082903_1.htm<\/a><\/p>\nJAIDS<\/h2>\n